午夜一级毛片-手机看片99-动漫人物桶机免费动漫app-日日摸日日碰夜夜97|www.zyjlr.com

TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
A monopoly on drug prices? Don't think about it
 
Author:中國銘鉉 企劃部  Release Time:2017-8-11 8:40:15  Number Browse:620
 
On August 10th, the medical website learned that the "guide to the price behavior of drug monopolization of shortage drugs" will be solicited from the public in the near future. Experts say that the introduction of the document will curb illegal price rises, malicious control and other behaviors, and it is of great significance for stabilizing drug prices and cooperating with health reform. 
 
Drugs is not normal supply of drugs in some area, the API is downstream pharmaceutical production enterprise production of pharmaceutical preparations necessary for chemical or natural ingredients, these changes of abnormal drug prices, medical relevant industries of normal operation and vital interests of the people will have a significant impact. 
 
Operators at present, our country's shortage of drugs and drug ingredients to frequent phenomenon of illegal pricing, objectively has the characteristics of scarcity due to shortage of drugs and drug ingredients, illegal pricing ACTS are criminals, profited destroy competition high-risk areas. Since 2011, the national price departments have dealt with promethazine hydrochloride, don't Piao alcohol, estazolam, isoniazid and other operator shortage of several drugs and drug ingredients to implement price monopoly. 
 
Experts say that with the deepening of the reform of China's medical and health system, the market has gradually established a mechanism for the pricing of drugs. By introducing guidance, standardize operator shortage of drugs and drug ingredients to price, to guide the related compliance in accordance with the business, to curb illegal behavior such as prices, malicious control pin, to stabilize prices, cooperate with the medical reform is of great significance. 
 
Expert proposal, based on the characteristics of the industry shortage of drugs and drug ingredients, the next step should be clear the relevant market definition and market dominance of standard elements, such as the industry nate some "underwriting agreement" "underwriting agreement" and other management behavior qualitative rules, this is also a kind of legitimacy to operator guidance. At the same time, the shortage of all kinds of monopoly in the field of active pharmaceutical ingredients and drug products, such as the form of monopoly agreements, abuse of dominant market position, its determination, the exemption conditions should also be specified. 
 
"This paper will be viewed as part of a policy combination of solutions to drug supply problems." A medical industry source, who declined to be named, told the economic reference newspaper that the medical monopoly was the focus of recent years in China. On the one hand, the current price laws and anti-monopoly laws and regulations in China are difficult to provide clear guidelines for the specific application of price behavior of shortage drugs and raw drug industry. Shortage, on the other hand, active pharmaceutical ingredients and drug price formation mechanism is very complex, monopoly behavior is difficult to determine, the new file to standardize market shortage of drugs and drug ingredients to illegal pricing ACTS, safeguard the order of the market price, the establishment of drug procurement fair market environment play an important role. 
 
But it is also hard for the drug industry to make a complete change in the current price environment for a shortage of medicines, according to a guide. He suggested that, given the illegal cost is too low, should intensify their efforts to fight monopoly on illegal behavior strictly processing, trading should prohibit abuse of dominant market position limit operator or additional unreasonable terms. Secondly, the price of medicines and raw materials can be rationalized by means of designated drug companies, which can increase government investigation and attention. In addition, increasing the import of raw materials should be one of the feasible methods. "Though traditionally, domestic drug companies have an advantage in the production of active pharmaceutical ingredients, but in recent years, India, Vietnam and other countries related industry has developed rapidly, API low cost low prices, quality guaranteed, and cross-border trade enterprise is difficult to form monopoly." He said. 
 
More recent targeted measures have been introduced to ensure the supply of scarce medicines. For example, jiangsu province will establish a management system for the dynamic list of shortage drugs. In shandong province this year set up the province's shortage of drug monitoring network, through the supply and demand information announcement, fixed-point business DiaoChu, market set, effectively relieve some of the drug shortage problem. 
 
Li bin, director of the national health development planning commission, points out that this year we need to promptly pay special attention to the six key task for the construction of drug supply security system, one of the first is to strengthen the construction of a shortage of drug supply security system, improve the linkage in consultation with and grading coping mechanism. At the end of June this year, many ministries jointly issued "on reform and improve the shortage of drug supply security mechanism of the implementation opinions", put forward in the present each province layout on the basis of not less than 15 monitoring sentinel, unicom register pharmaceutical research, procurement, production circulation use such as the key link, gradually formed national, provincial, city and county level monitoring network system and early warning mechanism. We will reasonably define the shortage of medicines for clinical needs, and establish a list management system for the national and provincial drug shortages, and release relevant information on a regular basis. 
 
According to the national level, the next step will be to focus on the national shortage of drug inventory, and organize the evaluation of the production and supply assurance capacity of shortage drugs and their raw materials. Provincial key is to establish a corresponding consultation with the linkage mechanism, comprehensive evaluation of drug shortage information within their respective jurisdictions and respond to Suggestions, as a whole the solve the problem of shortage of locality, timely report and deal with a shortage of information, analysis, strengthen comprehensive response ability. 

 
Previous article:2016 pharmaceutical giant layoffs: sanofi is the worst hit
Next article:The new scheme of "two-ticket system" in shandong province has been deleted
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粵公網(wǎng)安備 44011202000029號(hào)